MyFinsight
Home
Blog
About
Contact
Download
Download image
Stock-based compensation
expense
$348,235K
Net income (loss)
$313,747K
Sales and maturities
of marketable...
$1,802,257K
Non-cash interest
expense on liabilities...
$238,399K
Accounts payable,
accrued expenses and...
$75,066K
Depreciation and
amortization
$55,658K
Loss related to
convertible debt
-$42,473K
Inventory
-$8,474K
Realized and unrealized
loss on marketable...
-$2,306K
Proceeds from maturity of
restricted investments
$59,775K
Net cash provided by
(used in) operating...
$524,080K
Net cash provided by
(used in) investing...
$436,329K
Canceled cashflow
$560,278K
Effect of exchange rate
changes on cash, cash...
$34,936K
Canceled cashflow
$1,425,703K
Net increase
(decrease) in cash, cash...
$690,155K
Canceled cashflow
$305,190K
Accounts receivable, net
$359,963K
Prepaid expenses and
other assets
$117,724K
Deferred revenue
-$50,635K
Other
-$29,758K
Deferred income taxes
-$2,198K
Purchases of marketable
securities
$1,305,081K
Purchases of restricted
investments
$59,775K
Purchases of property,
plant and equipment
$58,697K
Other investing
activities
$2,150K
Proceeds from issuance of
0.00 convertible...
$645,692K
Proceeds from exercise of
stock options and...
$250,028K
Proceeds from
liabilities related to the...
$6,000K
Net cash (used in)
provided by financing...
-$305,190K
Canceled cashflow
$901,720K
Repayment of 1.00
convertible senior notes due...
$1,154,913K
Purchases of capped calls
related to 0.00...
$35,311K
Repayment of liabilities
related to the sale of...
$14,272K
Payment of issuance
costs for revolving...
$2,414K
Back
Back
Cash Flow
source: myfinsight.com
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
ALNYLAM PHARMACEUTICALS, INC. (ALNY)